These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22392961)

  • 1. Type 2 diabetes and insulin secretagogues.
    Hormone Foundation
    J Clin Endocrinol Metab; 2012 Mar; 97(3):37A-38A. PubMed ID: 22392961
    [No Abstract]   [Full Text] [Related]  

  • 2. Insulin responses to sulfonylureas.
    Cerasi E
    Diabetes Res Clin Pract; 2002 Apr; 56(1):69-70; author reply 71. PubMed ID: 11879723
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical efficacy of glimepiride].
    Kaneko T; Sakamoto N
    Nihon Rinsho; 1997 Nov; 55 Suppl():152-7. PubMed ID: 9434460
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pathophysiology of diabetes mellitus type 2 and the mechanism of action and indications for using hypoglycemic sulfonylurea derivatives].
    Tatoń J; Koliński P
    Pol Tyg Lek; 1985 May; 40(18):505-11. PubMed ID: 3892513
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypoglycaemic and anti-hyperglycaemic drugs for the control of diabetes.
    Bailey CJ
    Proc Nutr Soc; 1991 Dec; 50(3):619-30. PubMed ID: 1809970
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part I--"The pros".
    Waldhäusl W
    Horm Metab Res; 1996 Sep; 28(9):517-21. PubMed ID: 8911990
    [No Abstract]   [Full Text] [Related]  

  • 7. Does insulin preserve beta-cell function in type 2 diabetes?
    Heise T; Sawicki PT
    J Intern Med; 2002 Apr; 251(4):283-5. PubMed ID: 11952878
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of long-term therapy with sulfanylurea preparations on the relation of insulin secretion and the insulin-binding capacity of its receptors].
    Balabolkin MI; Nedosugova LV
    Ter Arkh; 1988; 60(12):91-6. PubMed ID: 3150136
    [No Abstract]   [Full Text] [Related]  

  • 9. Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management.
    Pontiroli AE; Calderara A; Pozza G
    Diabetes Metab Rev; 1994 Apr; 10(1):31-43. PubMed ID: 7956674
    [No Abstract]   [Full Text] [Related]  

  • 10. [Combined insulin and sulfonylurea treatment in diabetes mellitus].
    Ravina A; Minuhin O
    Harefuah; 1986 Jan; 110(1):11-4. PubMed ID: 3514394
    [No Abstract]   [Full Text] [Related]  

  • 11. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride.
    Korytkowski MT
    Pharmacotherapy; 2004 May; 24(5):606-20. PubMed ID: 15162895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin secretagogues: who, what, when, and how?
    Dailey G
    Curr Diab Rep; 2005 Oct; 5(5):329-32. PubMed ID: 16188166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress in studies on antidiabetic agents].
    Tang L; Yang YS; Ji RY
    Yao Xue Xue Bao; 2001 Sep; 36(9):711-5. PubMed ID: 12580115
    [No Abstract]   [Full Text] [Related]  

  • 14. Diabetes care: what should we try to achieve?
    O'Connor PJ
    J Fam Pract; 1991 Oct; 33(4):343-4. PubMed ID: 1919448
    [No Abstract]   [Full Text] [Related]  

  • 15. [Approaches in diabetes therapy. 2. Selection and use of oral antidiabetics. 1) Drugs enhancing insulin secretion].
    Yoshimoto K; Ishida H
    Nihon Naika Gakkai Zasshi; 2000 Aug; 89(8):1523-9. PubMed ID: 11062899
    [No Abstract]   [Full Text] [Related]  

  • 16. ATP-sensitive K+ channels and insulin secretion: their role in health and disease.
    Ashcroft FM; Gribble FM
    Diabetologia; 1999 Aug; 42(8):903-19. PubMed ID: 10491749
    [No Abstract]   [Full Text] [Related]  

  • 17. Do sulfonylureas influence hepatic insulin clearance?
    Groop LC; Groop PH; Stenman S; Saloranta C; Tötterman KJ; Fyhrquist F; Melander A
    Diabetes Care; 1988 Sep; 11(8):689-90. PubMed ID: 3065007
    [No Abstract]   [Full Text] [Related]  

  • 18. New pharmacologic approaches to the treatment of diabetes.
    Johnson DG; Bressler R
    Spec Top Endocrinol Metab; 1984; 6():163-92. PubMed ID: 6151747
    [No Abstract]   [Full Text] [Related]  

  • 19. Rapid-acting insulin secretagogues: a clinical need?
    Home PD
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S115-9. PubMed ID: 10522834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview.
    Beck-Nielsen H; Hother-Nielsen O; Pedersen O
    Diabet Med; 1988 Oct; 5(7):613-20. PubMed ID: 2975544
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.